What is NDC 49281-026?

49281-026 is the product NDC for Nuvaxovid 2026-27 (nvx-cov2928), Nvx-cov2928 5 ug/.5mL injection, suspension, listed with the FDA by Sanofi Vaccines US Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Nuvaxovid 2026-27 (Nvx-cov2928).

Sanofi Vaccines US Inc., NDC labeler code 49281. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Nuvaxovid 2026-27?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Nuvaxovid 2026-27 NDC 49281-026 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)49281-026Labeler and product segments. Claims need a package NDC.

Product NDC at billing width49281-0026Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
49281-026-50	4928100265049281002650	10 SYRINGE in 1 CARTON (49281-026-50) / .5 mL in 1 SYRINGE (49281-026-88)Marketed from Aug 27, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Nuvaxovid 2026-27
Generic name (nonproprietary): nvx-cov2928
Active ingredients: Nvx-cov2928 — 5 ug/.5mL
Dosage form: Injection, Suspension
Route: Intramuscular
Labeler: Sanofi Vaccines US Inc.NDC labeler code 49281
Product type: Vaccine
Marketing category: BLA — Biologics License ApplicationApplication BLA 125817
Marketing start: Aug 27, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 49281-026_7c54fe54-5938-4350-b3e9-08878951bedcSPL ID 7c54fe54-5938-4350-b3e9-08878951bedc

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Immunization administration (CPT 90460–90474)

Giving a vaccine is reported separately from the vaccine product code, with an immunization administration code. Which code applies depends on the patient's age, the route and whether counselling was provided.

How CPT relates to drug billing

NDC on a medical claim

N449281002650 followed by a unit qualifier and the quantity

Package 49281-0026-50. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

About NDC 49281-026

What is NDC 49281-026?: 49281-026 is the product NDC for Nuvaxovid 2026-27 (nvx-cov2928), Nvx-cov2928 5 ug/.5mL injection, suspension, listed with the FDA by Sanofi Vaccines US Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Nuvaxovid 2026-27 (Nvx-cov2928).
What is the active ingredient?: Nvx-cov2928.
Who is the labeler?: Sanofi Vaccines US Inc., NDC labeler code 49281. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Nuvaxovid 2026-27?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Nuvaxovid 2026-27 (Nvx-cov2928) NDC 49281-026